Stock Groups

U.S. FDA delays decision on Moderna’s COVID-19 vaccine for adolescents

by Mike Robinson

[ad_1]

© Reuters. FILE PHOTO – Test tubes seen in front a Moderna logo displayed in this illustration, taken May 21, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters] – A U.S. regulatory body for healthcare is putting off a decision about authorizing Moderna (NASDAQ:) Inc’s COVID-19 vaccine was given to adolescents in an effort to determine if it could cause heart inflammation. The Wall Street Journal reported Friday that the shots were being tested by people who are familiar with the situation.

Moderna’s stock fell almost 2% to $326.25 midday after the report.

U.S. Food and Drug Administration has begun to investigate the possibility of myocarditis in younger men who have received Moderna’s vaccine, particularly when compared with Pfizer The Wall Street Journal reported that the vaccine was approved by the NYSE after some Nordic countries had restricted their use.

According to the report, it is not clear if there are heightened risks.

Due to myocarditis in some men, Finland, Sweden, and Denmark stopped using Moderna’s COVID-19 shots for young males earlier this month.

However, the Danish Health Agency later stated that vaccines are available for under-18s and that Wednesday’s statement suggesting suspension was a miscommunication.

Moderna and FDA have not yet responded to comment requests.

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media or any other person involved in the website will not be held responsible for any loss or damage resulting from reliance on this information, including charts, buy/sell signals, and data. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]